Applications published 4 March 2009

Combination antidepressants wafer
LTS Lohmann Therapie-Systeme 2029097*

• Smoking withdrawal combination wafer
LTS Lohmann Therapie-Systeme 2029098*

• Combination antihypertensive wafer
LTS Lohmann Therapie-Systeme 2029099*

• ACHE-NMDA combination wafer
LTS Lohmann Therapie-Systeme 2029100*

• Type-2 diabetes combination wafer
LTS Lohmann Therapie-Systeme 2029101*

• Opioid combination wafer
LTS Lohmann Therapie-Systeme 2029102*

• VEGF antagonist formulations suitable for intravitreal administration
Regeneron Pharmaceuticals 2029103*

• Suppository for haemorrhoid treatment
Takeshira, Jiro 2029104*

• Phenylphrine pulsed release formulations and pharmaceutical compsns
Schering 2029105*

• Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical comspsn thereof
Foamix 2029106*

• Utilisation of vinyl acetate sulphonate copolymers as solubilisers for compounds with low solubility in water
BASF 2029107*

• High performance reticulated elastomeric matrix
Biomerix 2029108*

• Method for preparing polymeric matrices by radiation in the presence of sensitive pharmaceutical compounds
DSM IP 2029109*

• Process for preparing spray dried formulations of TMC125
Tibotec Pharmaceuticals 2029110*

• Microparticles and methods for production thereof
Baxter International; Baxter Healthcare 2029111*

• Pharmaceutical compsn comprising hydrochlorothiazide and telmisartan
Lek Pharmaceuticals 2029112*

• Process for making multiparticles using a roller compactor
Novartis 2029113*

• Pharmaceutical compsns for sustained release of phenylephrine
Schering 2029114*

• Disposable infusion device with linear peristaltic pump
Calibra Medical 2029115*

• Segmented pharmaceutical dosage forms
Accu-Break Technologies 2029116*

• Rapid dissolution of combination products
Teva Pharmaceutical Industries 2029117*

• Oxcarbazepine pharmaceutical formulation, and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
Teva Pharmaceutical Industries 2029118*

• Functionalised solid polymer nanoparticles for diagnostic and therapeutic applications
Bayer Schering Pharma Aktiengesellschaft 2029119*

• Nanoparticles containing three various ligands for providing immune responses against infectious agents
Midatech 2029120*

• Transdermal therapeutic system comprising active ingredient particles and having increased active ingredient flux
LTS Lohmann Therapie-Systeme 2029121*

• Autodestructive transdermal therapeutic system
LTS Lohmann Therapie-Systeme 2029122*

• Use of a compound with RANKL activity
IMBA-Institut fuer Molekulare Biotechnologie 2027123*

• Use of GPCR agonists to delay progression of diabetes
Prosidion 2029124*

• Pharmaceutical compsn for the treatment of viral infections and/or tumour diseases by inhibiting protein folding and protein breakdown
ViroLogik 2029125*

• Novel medicament combinations for the treatment of respiratory diseases
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2029126*

• New long-acting drug combinations for the treatment of respiratory diseases
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2029127*

• Method of treatment of chronic nonbacterial prostatitis with selective oestrogen receptor modulators or aromatase inhibitors
Hormos Medical 2029128*

• Gestagen combination and an insulin sensitiser for treating PCOS
Gruenenthal 2029129*

• Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
Newron Pharmaceuticals 2029130*

• Method for treating renal disease
MCW Research Foundation 2029131*

• Anti-histamine compsns and use thereof
Taro Pharmaceuticals 2029132*

• Compsns comprising at least one naphthoic acid derivative and at least one film-forming agent, methods for preparing same, and uses thereof
Galderma Research & Development 2029133*

• Stabilised pharmaceutical compsns comprising fesoterodine
Schwarz Pharma 2029134*

• Epoxide inhibitors of cysteine proteases
The Board of Trustees of the Leland Stanford Junior University 2029135*

• Treatment for depressive disorders
Vanda Pharmaceuticals 2029136*

• Antihypertensive therapy method
Gilead Colorado 2029137*

• Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
Xenon Pharmaceuticals 2029138*

• Use of a P38 kinase inhibitor for treating psychiatric disorders
SmithKline Beecham 2029139*

• Stable and bioavailable formulations and a novel form of desloratadine
Sandoz 2029140*

• Combination of somatostatin-analogs with dopamine- or growth receptor antagonist
Novartis 2029141*

• Compsn for induction or inhibition of stem cell differentiation
Choongwae Pharma 2029142*

• Substituted 8-(6-amino-3-pyridyl) xanthines
PGX Health 2029143*

• Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
Novartis 2029144*

• Pyrrolopyrimidine compounds and their uses
Novartis; Astrex Therapeutics 2029145*

• Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
Warner Chilcott 2029146*

• Methods for treating cancer
Ramot at Tel Aviv University 2029147*

• Antimicrobial carbon
Merck Patent 2029148*

• Immune privileged and modulatory progenitor cells
Davies, John; Ennis, Jane; Gomez-Artistizabal, Alejandro; Baksh, Dolores 2029149*

• Extract of herbal and the compsn containing the same
Dong-A Pharm 2029150*

• Method of preparing dialysed extract of fenugreek seeds
Department of Biotechnology 2029151*

• Compsn comprising at least one higher aliphatic alcohol and an extract of Griffonia simplicifolia
Panacea Biotec 2029152*

• Hepatitis C serine protease inhibitors and uses therefor
Phenomix; Campbell, David; Hepperle, Michael; Winn, David; Betancourt, Juan 2029153*

• Treatment of melanoma
Sciclone Pharmaceuticals 2029154*

• Improved antitumoural treatments
Pharma Mar 2029155*

• Combination therapy for treatment of cancer
University of Southern California 2029156*

• ABC transporter ligand
Georgia Tech Research 2029157*

• Pharmaceutical compsn comprising apolipoproteins for the treatment of human diseases
Universite Libre de Bruxelles 2029158*

• Compsns and methods for modulating vascular development
Genentech 2029159*

• Methods to restore glycaemic control
Amylin Pharmaceuticals; Eli Lilly 2029160*

• Use of non-catalytic form of heparanase and peptides thereof for reversing the anti-coagulant effects of heparinoids
Hadasit Medical Research Services and Development; The Medical Research Fund at the Tel Aviv Sourasky Medical Centre 2029161*

• Compsn for controlling snoring in the form of a nasal spray
Moega Pharma Capital NV 2029162*

• Lyophilised formulations of anti-EFGR antibodies
ImClone Systems 2029163*

• Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
The Board of Trustees of the Leland Stanford Junior University; Department of Veterans Affairs; Fabgene, Paolo; Constantin, Gabriela 2029164*

• B cell-based vaccine loaded with the ligand of natural killer T cell and antigen
Seoul National University Industry Foundation 2029165*

• HIV-1 clade A consensus sequences, antigens and transgenes
International Aids Vaccine Initiative 2029168*

• Recombinant viral vaccine
Transgene 2029169*

• Quality control methods for oil-in-water emulsions containing squalene
Novartis 2029170*

• Methods of modulating IL-22 and IL-17
Wyeth 2029171*

• Anti-C35 antibodies for treating cancer
Vaccinex 2029172*

• FC RIIB-specific antibodies and methods of use thereof
MacroGenics 2029173*